全文获取类型
收费全文 | 3031篇 |
免费 | 261篇 |
国内免费 | 30篇 |
专业分类
耳鼻咽喉 | 21篇 |
儿科学 | 178篇 |
妇产科学 | 36篇 |
基础医学 | 410篇 |
口腔科学 | 111篇 |
临床医学 | 249篇 |
内科学 | 531篇 |
皮肤病学 | 93篇 |
神经病学 | 196篇 |
特种医学 | 200篇 |
外国民族医学 | 1篇 |
外科学 | 620篇 |
综合类 | 62篇 |
一般理论 | 1篇 |
预防医学 | 196篇 |
眼科学 | 72篇 |
药学 | 115篇 |
中国医学 | 3篇 |
肿瘤学 | 227篇 |
出版年
2023年 | 27篇 |
2022年 | 28篇 |
2021年 | 61篇 |
2020年 | 34篇 |
2019年 | 41篇 |
2018年 | 75篇 |
2017年 | 78篇 |
2016年 | 82篇 |
2015年 | 95篇 |
2014年 | 124篇 |
2013年 | 168篇 |
2012年 | 147篇 |
2011年 | 156篇 |
2010年 | 152篇 |
2009年 | 149篇 |
2008年 | 118篇 |
2007年 | 135篇 |
2006年 | 116篇 |
2005年 | 94篇 |
2004年 | 111篇 |
2003年 | 70篇 |
2002年 | 73篇 |
2001年 | 75篇 |
2000年 | 50篇 |
1999年 | 68篇 |
1998年 | 121篇 |
1997年 | 96篇 |
1996年 | 117篇 |
1995年 | 70篇 |
1994年 | 83篇 |
1993年 | 50篇 |
1992年 | 30篇 |
1991年 | 33篇 |
1990年 | 29篇 |
1989年 | 42篇 |
1988年 | 39篇 |
1987年 | 34篇 |
1986年 | 32篇 |
1985年 | 32篇 |
1984年 | 15篇 |
1983年 | 16篇 |
1982年 | 26篇 |
1981年 | 16篇 |
1980年 | 18篇 |
1979年 | 12篇 |
1978年 | 9篇 |
1977年 | 10篇 |
1976年 | 14篇 |
1975年 | 13篇 |
1974年 | 8篇 |
排序方式: 共有3322条查询结果,搜索用时 15 毫秒
1.
Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma
2.
3.
4.
P Avalos-Peralta† A Herrera† JJ Ríos-Martín‡ AM Pérez-Bernal† D Moreno-Ramírez† F Camacho† 《Journal of the European Academy of Dermatology and Venereology》2006,20(1):79-83
We report the case of a patient with a 13-year history of pemphigus vulgaris (PV) treated with immunosuppressive agents, prednisone and mycophenolate mofetil who had developed lesions of Kaposi's sarcoma (KS) on a sole plaque of PV that had been previously treated with intralesional injections of steroids. The lesions were surgically removed and polymerase chain reaction (PCR) demonstrated human herpesvirus-8 (HHV-8) DNA. There were neither recurrences nor later dissemination of KS following gradual decrease of the immunosuppressive therapy. We suggest that the treatment with intralesional steroids may have influenced the local reactivation of a latent infection of the virus, determining the appearance of this localized KS. 相似文献
5.
6.
7.
J. Duteil FA Rambert AM Pointeau P. Mangiameli and E. Assous 《Fundamental & clinical pharmacology》1991,5(8):695-708
The potential antidepressant effect of flerobuterol (dl-(fluoro-2 phenyl)-1 t-butylamino-2 ethanol), a new drug related to beta-adrenoceptor agonists, was evaluated and compared with imipramine and salbutamol using classical psychopharmacological tests in mice. Like imipramine and salbutamol, flerobuterol (0.5-32 mg kg-1, ip) fully prevented apomorphine (16 mg kg-1, sc)- and partly reversed reserpine- and oxotremorine-induced hypothermia. At higher doses (16-32 mg kg-1), flerobuterol enhanced the toxic effects of yohimbine. Unlike imipramine, flerobuterol and salbutamol did not reduce immobility duration in the behavioural despair test. Salbutamol and flerobuterol decreased locomotor activity. Flerobuterol did not induce mydriasis, did not prevent oxotremorine-induced tremors or salivary and lacrimal gland secretion and did not reduce reserpine-induced palpebral ptosis. Propranolol (8 mg kg-1, ip) but not alpha-methyl-paratyrosine (75 mg kg-1, ip) prevented the flerobuterol-induced antagonism of apomorphine-induced hypothermia. Our results suggest that flerobuterol demonstrates potential antidepressant activity, which could be related to beta-adrenoceptor activation in mice. 相似文献
8.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
9.
Hung-Fat Tse Sukumaran Thambar Yok-Lam Kwong Philip Rowlings Greg Bellamy Jane McCrohon Paul Thomas Bruce Bastian John K F Chan Gladys Lo Chi-Lai Ho Wing-Sze Chan Raymond Y Kwong Anthony Parker Thomas H Hauser Jenny Chan Daniel Y T Fong Chu-Pak Lau 《European heart journal》2007,28(24):2998-3005
AIMS: Experimental studies have demonstrated that bone marrow (BM) cells can induce angiogenesis in ischaemic myocardium. Recently, several non-randomized pilot studies have also suggested that direct BM cells implantation appears to be feasible and safe in patients with severe coronary artery diseases (CAD). METHODS AND RESULTS: We performed a randomized, blinded, and placebo-controlled trial in 28 CAD patients. After BM harvesting, we assigned patients to receive low dose (1 x 10(6) cells/0.1 mL, n = 9), high dose (2 x 10(6) cells/0.1 mL, n = 10) autologous BM cells or control (0.1 mL autologous plasma/injection, n = 9) catheter-based direct endomyocardial injection as guided by electromechanical mapping. Our primary endpoint was the increase in exercise treadmill time and our secondary endpoints were changes in Canadian Cardiovascular Society (CCS) and New York Heart Association (NYHA) class, and myocardial perfusion and left ventricular ejection fraction (LVEF) assessed by single-photon emission computed tomography and magnetic resonance imaging, respectively. A total 422 injections (mean 14.6 +/- 0.7 per patient) were successfully performed at 41 targeted ischaemic regions without any acute complication. Baseline exercise treadmill time was 439 +/- 182 s in controls and 393 +/- 136 s in BM-treated patients, and changed after 6 months to 383 +/- 223s and 464 +/- 196 s [BM treatment effect +0.43 log seconds (+53%), 95% CI 0.11-0.74, P = 0.014]. Compared with placebo injection, BM implantation was associated with a significant increase in LVEF (BM treatment effect +5.4%, 95% CI 0.4-10.3, P = 0.044) and a lower NYHA class (odds ratio for treatment effect 0.12, 95% CI 0.02-0.73, P = 0.021) after 6 months, but CCS reduced similarly in both groups. We observed no acute or long-term complications, including ventricular arrhythmia, myocardial damage, or development of intramyocardial tumour or calcification associated with BM implantation. CONCLUSION: Direct endomyocardial implantation of autologous BM cells significantly improved exercise time, LVEF, and NYHA functional class in patients with severe CAD who failed conventional therapy. 相似文献
10.